© Reuters. FILE PHOTO: A sign marks Novartis’ Institutes for Biomedical Research in Cambridge, Massachusetts, U.S., January 2, 2020. Picture taken January 2, 2020. REUTERS/Brian Snyder/File Photo
(Reuters) – Quarterly operating income at Swiss drugmaker Novartis slipped as competition weighed on prescriptions of multiple sclerosis drug Gilenya.
For Novartis, which reports results in dollars, a strong U.S. currency was also a drag on the value of sales generated outside the United States.
Third-quarter core operating income declined 4% to $4.28 billion, slightly below the average analyst consensus of $4.30 billion.
Be the first to comment